Freda PU et al. (2005) Long-acting somatostatin analog therapy of acromegaly: a meta-analysis. J Clin Endocrinol Metab 90: 4465-4473
Petrossians P et al. (2005) Gross total resection or debulking of pituitary adenomas improves hormonal control of acromegaly by somatostatin analogs. Eur J Endocrinol 152: 61-66
de Herder WW et al. (2005). Limited predictive value of an acute test with subcutaneous octreotide for long-term IGF-I normalization with sandostatin LAR in acromegaly. Eur J Endocrinol 153: 67-71
Colao A et al. (1996) Prediction of efficacy of octreotide therapy in patients with acromegaly. J Clin Endocrinol Metab 81: 2356-2362
Park C et al. (2004) Somatostatin (SRIF) receptor subtype 2 and 5 gene expression in growth hormone-secreting pituitary adenomas: the relationship with endogenous SRIF activity and response to octreotide. Endocr J 51: 227-236
